George V. Papatheodoridis mainly focuses on Internal medicine, Gastroenterology, Hepatitis B, Immunology and Hepatitis B virus. His research in Internal medicine intersects with topics in Endocrinology and Pathology. George V. Papatheodoridis studies Gastroenterology, namely Cirrhosis.
His biological study spans a wide range of topics, including Entecavir, Hepatology and Viral hepatitis. His Lamivudine, HBsAg and Alpha interferon study in the realm of Immunology connects with subjects such as Chemistry. His Hepatitis B virus research includes elements of Liver cancer, Viremia, Combination therapy and Viral load.
George V. Papatheodoridis focuses on Internal medicine, Gastroenterology, Immunology, Cirrhosis and Hepatitis B. The Hepatocellular carcinoma research George V. Papatheodoridis does as part of his general Internal medicine study is frequently linked to other disciplines of science, such as In patient, therefore creating a link between diverse domains of science. His Gastroenterology research incorporates elements of HBsAg, Lamivudine, Liver transplantation and Liver biopsy.
His studies in Liver biopsy integrate themes in fields like Steatohepatitis and Fatty liver. The concepts of his Cirrhosis study are interwoven with issues in Hepatitis C, Hepatitis, Fibrosis, Ribavirin and Cohort. George V. Papatheodoridis has researched Hepatitis B in several fields, including Viral hepatitis and Hepatitis B virus.
His scientific interests lie mostly in Internal medicine, Gastroenterology, Cirrhosis, Chronic hepatitis and Hepatocellular carcinoma. In the subject of general Internal medicine, his work in Hepatitis B is often linked to In patient, thereby combining diverse domains of study. The various areas that George V. Papatheodoridis examines in his Gastroenterology study include Hazard ratio, Liver transplantation, Tenofovir and Fatty liver.
His Cirrhosis research integrates issues from Liver biopsy, Viral hepatitis, Liver disease, Etiology and Cohort. His work in Chronic hepatitis addresses issues such as Hbeag negative, which are connected to fields such as Prospective cohort study. His work carried out in the field of Hepatocellular carcinoma brings together such families of science as Framingham Risk Score, Oncology and Colorectal surgery.
His primary scientific interests are in Internal medicine, Cirrhosis, Gastroenterology, Hepatitis B and Hepatocellular carcinoma. George V. Papatheodoridis has included themes like HBsAg, Hepatitis B virus and Chronic hepatitis in his Internal medicine study. George V. Papatheodoridis works mostly in the field of Hepatitis B virus, limiting it down to concerns involving Hepatitis and, occasionally, Clinical trial, HBeAg and Clinical endpoint.
George V. Papatheodoridis interconnects Liver disease, Etiology, Cohort and Sofosbuvir in the investigation of issues within Cirrhosis. As a part of the same scientific study, George V. Papatheodoridis usually deals with the Gastroenterology, concentrating on Entecavir and frequently concerns with Incidence. His study looks at the relationship between Hepatocellular carcinoma and fields such as Framingham Risk Score, as well as how they intersect with chemical problems.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection.
Pietro Lampertico;Kosh Agarwal;Thomas Berg;Maria Buti.
Journal of Hepatology (2017)
Global prevalence and genotype distribution of hepatitis C virus infection in 2015: a modelling study
Sarah Blach;Stefan Zeuzem;Michael Manns;Ibrahim Altraif.
The Lancet Gastroenterology & Hepatology (2017)
2-Year GLOBE Trial Results: Telbivudine Is Superior to Lamivudine in Patients With Chronic Hepatitis B
Yun–Fan Liaw;Edward Gane;Nancy Leung;Stefan Zeuzem.
Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study
Devin Razavi-Shearer;Ivane Gamkrelidze;Mindie H Nguyen;Ding-Shinn Chen.
The Lancet Gastroenterology & Hepatology (2018)
Efficacy of long‐term lamivudine monotherapy in patients with hepatitis B e antigen–negative chronic hepatitis B
Stephanos J. Hadziyannis;George V. Papatheodoridis;Evangelini Dimou;Andreas Laras.
Incidence of hepatocellular carcinoma in chronic hepatitis B patients receiving nucleos(t)ide therapy: a systematic review.
George V. Papatheodoridis;Pietro Lampertico;Spilios Manolakopoulos;Anna Lok.
Journal of Hepatology (2010)
Systematic review: The model for end-stage liver disease--should it replace Child-Pugh's classification for assessing prognosis in cirrhosis?
E. Cholongitas;G. V. Papatheodoridis;M. Vangeli;N. Terreni.
Alimentary Pharmacology & Therapeutics (2005)
Transjugular intrahepatic portosystemic shunt compared with endoscopic treatment for prevention of variceal rebleeding: A meta-analysis.
George V. Papatheodoridis;John Goulis;Gioacchino Leandro;David Patch.
The long-term outcome of interferon-α treated and untreated patients with HBeAg-negative chronic hepatitis B
George V Papatheodoridis;Emanuel Manesis;Stephanos J Hadziyannis.
Journal of Hepatology (2001)
Tenofovir disoproxil fumarate (TDF), emtricitabine/TDF, and entecavir in patients with decompensated chronic hepatitis B liver disease.
Yun‐Fan Liaw;I‐Shyan Sheen;Chuan‐Mo Lee;Ulus Salih Akarca.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: